BCDA vs. BRNS, JSPR, NBRV, ANVS, AADI, LTRN, TPST, ATHE, XFOR, and TELO
Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Barinthus Biotherapeutics (BRNS), Jasper Therapeutics (JSPR), Nabriva Therapeutics (NBRV), Annovis Bio (ANVS), Aadi Bioscience (AADI), Lantern Pharma (LTRN), Tempest Therapeutics (TPST), Alterity Therapeutics (ATHE), X4 Pharmaceuticals (XFOR), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry.
BioCardia vs. Its Competitors
Barinthus Biotherapeutics (NASDAQ:BRNS) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.
25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 20.0% of BioCardia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Barinthus Biotherapeutics' return on equity of -54.70% beat BioCardia's return on equity.
Barinthus Biotherapeutics presently has a consensus target price of $3.00, indicating a potential upside of 163.16%. BioCardia has a consensus target price of $25.00, indicating a potential upside of 1,084.83%. Given BioCardia's stronger consensus rating and higher possible upside, analysts plainly believe BioCardia is more favorable than Barinthus Biotherapeutics.
In the previous week, BioCardia had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 2 mentions for BioCardia and 0 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 1.00 beat BioCardia's score of 0.04 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.
Barinthus Biotherapeutics has a beta of -0.75, meaning that its stock price is 175% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.
BioCardia has lower revenue, but higher earnings than Barinthus Biotherapeutics. BioCardia is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Barinthus Biotherapeutics and BioCardia tied by winning 8 of the 16 factors compared between the two stocks.
Get BioCardia News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCardia Competitors List
Related Companies and Tools
This page (NASDAQ:BCDA) was last updated on 9/9/2025 by MarketBeat.com Staff
